Kiniksa Pharmaceuticals, Ltd. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Kiniksa Pharmaceuticals, Ltd. | KNSA - NASDAQ |
$17.00-$19.00 |
$18.00 |
$24.45 | 8.5 million | 5/24/2018 |
Goldman Sachs, J.P. Morgan |
Co-Manager(s): JMP Securities, Wedbush PacGrow |
Health Care |
Filing(s): Filed 2018-04-27 Terms Added 2018-05-14 Final Prospectus 2018-05-24
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Kiniksa Pharmaceuticals, Ltd., and our comprehensive analysis, click "Buy Market Research".
Kiniksa Pharmaceuticals, Ltd. Quote & Chart - Click for current quote -
KNSA
About Kiniksa Pharmaceuticals, Ltd. (adapted from Kiniksa Pharmaceuticals, Ltd. prospectus):
They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "KNSA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved